The metabolic switch caused by MYBBP1A downregulation through both c‐MYB and PGC1α activation is translated to increased proliferation in low‐glucose microenvironments, providing cells a competitive advantage to survive in restrictive microenvironments and confirming the tumor suppressor activity of MYBBP1A. The gene discussed is MYB; the disease is neoplasm.